Anapen is an autoinjector of epinephrine which is generally utilized by patients with critical allergies and a risk of anaphylactic shock since they can be self-administered and operate speedily.
Although disappointing to lose a product line, the Anapen contract did deliver a net positive return to the company.
19 September 2011 - UK specialty pharmaceutical company Allergy Therapeutics plc (LON:AGY) announced today it had received the exclusive distribution rights in UK and Ireland for the epinephrine pen auto injector, Anapen, for GBP600,000 (USD942,000/EUR689,000).
Anapen is already available in UK and Ireland, and Allergy Therapeutics expects sales of up to GBP2m in those countries over the next 12 months.
The company has been distributing Anapen in The Netherlands since September 2010 and has also obtained exclusive rights for Italy, Spain, Belgium, Poland, Argentina, Venezuela, Colombia and Chile.